Corticeira Amorim (0O7J)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 6.805 |
|---|---|
| 52-week range | 6.020 – 7.440 |
| Return, 1 month / 3 months | −2.8% / +3.0% |
| Return, 1 year / 3 years | −1.6% / −15.7% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 48 |
| Volatility (1 year) | 17.9% |
| Worst drawdown (1 year) | -16.2% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | 5.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Corticeira Amorim is a Portuguese company that turns cork bark into a range of products. Its main business is making cork stoppers for wine and sparkling wine bottles, and it also produces cork-based materials used in flooring, insulation, footwear and other industrial applications. The company is based in Mozelos, in northern Portugal, and serves drinks producers, builders and manufacturers in markets around the world.
On this site Corticeira Amorim appears as a stock on the London Exchange (UK), code 0O7J, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Corticeira Amorim (0O7J) trades on the London Exchange in UK. It last closed at EUR 6.805 on 22 October 2026.
Its price-based Market X-Ray is 64 out of 100 (a fair price profile), ranking 994 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 1.6% and over the last three months it rose 3.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 68 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.9% | ||
| From 52-week high | -7.7% | ||
| Momentum | 60 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 2.9% | ||
| 6-month return | 8.7% | ||
| 12-month return, skipping the last month | 1.2% | ||
| Stability (higher is calmer) | 87 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 17.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.2% | ||
| Liquidity | 15 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 8.3% | ||
| Income | 81 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 5.1% | ||
| Years with dividends | 6 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +2.0% |
|---|---|
| 1 month | −2.8% |
| 3 months | +3.0% |
| 6 months | +8.7% |
| 1 year | −1.6% |
| 3 years | −15.7% |
| 5 years | −34.1% |
Signals
| 50-day / 200-day average | 6.919 / 6.553 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.200 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 May 2026 | EUR 0.3500 |
| 23 May 2025 | EUR 0.3200 |
| 16 Dec 2024 | EUR 0.0900 |
| 20 May 2024 | EUR 0.2000 |
| 18 Dec 2023 | EUR 0.0900 |
| 11 May 2023 | EUR 0.2000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.